IP Library Granted Patent US 10,137,097
Granted Patent B2
US 10,137,097 · App. 15/574,651 · Granted Nov 27, 2018

Non-peptidic GAPDH aggregation inhibitor

Inventor: Hidemitsu Nakajima (Sakai, JP)
Assignee: OSAKA PREFECTURE UNIVERSITY PUBLIC CORPORATION
A61K31/16A61K31/10A61K31/164A61P25/16A61P25/28C07C323/57
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,137,097
App. No.
15/574,651
Granted
Nov 27, 2018
Kind
B2
Abstract

[Problem] Provided is a non-peptide compound which can be used as a GAPDH aggregation inhibitor. [Solution] Provided is a GAPDH aggregation inhibitor including as an active ingredient a compound represented by the chemical formula 1 wherein R 1 , R 2 , and R 3 are each independently a hydrogen atom, a halogen atom, or an aliphatic hydrocarbon group having a carbon number of from 1 to 10, a polysulfurized derivative thereof, or a pharmaceutically acceptable salt thereof. The present compound has a GAPDH aggregation inhibitory activity to suppress intracerebral aggregation of various proteins involved in cerebral neurodegenerative diseases, thereby contributing to improvement in various brain neurological diseases associated with aggregation of these proteins such as Alzheimer's disease, Parkinson's disease, and cerebral infarction, and prevention of advanced seriousness of these diseases.

Claims (3)

1. A compound represented by any of the chemical formula 1 wherein R 1 , R 2 , and R 3 are each independently a hydrogen atom, a halogen atom, or an aliphatic hydrocarbon group having a carbon number of from 1 to 10, the chemical formula 2 wherein R 1 , R 2 , and R 3 are each independently a hydrogen atom, a halogen atom, or an aliphatic hydrocarbon group having a carbon number of from 1 to 10, and n is an integer of 1 or more, or the chemical formula 3 wherein R 1 , R 2 , and R 3 are each independently a hydrogen atom, a halogen atom, or an aliphatic hydrocarbon group having a carbon number of from 1 to 10, and n is an integer of 1 or more, and a pharmaceutically acceptable salt thereof

2. A GAPDH aggregation inhibitor including as an active ingredient one or more compounds selected from the group consisting of a compound represented by any of the chemical formula 1 wherein R 1 , R 2 , and R 3 are each independently a hydrogen atom, a halogen atom, an aliphatic hydrocarbon group having a carbon number of from 1 to 10, the chemical formula 2 wherein R 1 , R 2 , and R 3 are each independently a hydrogen atom, a halogen atom, or an aliphatic hydrocarbon group having a carbon number of from 1 to 10, and n is an integer of 1 or more, or the chemical formula 3 wherein R 1 , R 2 , and R 3 are each independently a hydrogen atom, a halogen atom, or an aliphatic hydrocarbon group having a carbon number of from 1 to 10, and n is an integer of 1 or more, and a pharmaceutically acceptable salt thereof

3. A pharmaceutical composition comprising the compound according to claim 1 .

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Oct 29, 2020
From: OSAKA PREFECTURE UNIVERSITY PUBLIC CORPORATION; OSAKA CITY UNIVERSITY
To: UNIVERSITY PUBLIC CORPORATION OSAKA
Reel/Frame 054554/0465 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2017
From: NAKAJIMA, HIDEMITSU
To: OSAKA PREFECTURE UNIVERSITY PUBLIC CORPORATION
Reel/Frame 044154/0368 →
Priority Claims (1)
JP 2015-116140 · Jun 8, 2015 · national
Continuity (1)
Related Publication 20180116981A1 · May 3, 2018